PDEX · XBRL financial data

Pro-Dex financial statements, every fiscal year

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PDEX's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue	38,029	42,041	46,087	53,844	66,593	77,548
Cost of revenue	24,454	28,909	33,338	39,293	47,083	53,213
Gross profit	13,575	13,132	12,749	14,551	19,510	24,335
Research and development	4,384	2,980	2,804	3,189	3,636	3,345
Selling, general and administrative	—	—	—	—	5,185	7,999
General and administrative	4,076	4,903	4,028	4,072	4,841	—
Total operating expenses	9,050	8,009	6,987	7,378	8,821	11,344
Operating income (loss)	4,525	5,123	5,762	7,173	10,689	12,991
Interest expense	352	464	533	558	829	812
Income tax expense (benefit)	1,176	851	2,354	507	3,080	4,353
Net income (loss)	4,450	3,855	7,074	2,127	8,978	13,662
Earnings per share, basic USD per share	1.17	1.06	1.98	0.61	2.73	4.24
Earnings per share, diluted USD per share	1.13	1.02	1.95	0.60	2.67	4.12
Weighted average shares, basic thousands of shares	3,797	3,636	3,571	3,499	3,288	3,226
Weighted average shares, diluted thousands of shares	3,936	3,763	3,637	3,571	3,361	3,317

Fiscal years (PDEX's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	3,721	849	2,936	2,631	419	8,192
Short-term investments	1,295	755	1,134	4,217	6,740	1,150
Marketable securities	1,295	755	1,134	4,217	6,740	1,150
Marketable securities, non-current	1,704	1,779	1,361	1,563	148	154
Accounts receivable	10,933	15,384	9,952	13,887	16,433	21,205
Inventory	8,437	12,678	16,167	15,269	22,213	21,458
Prepaid and other current assets	434	790	296	345	410	—
Total current assets	25,013	31,166	30,979	36,611	47,295	53,248
Property and equipment, net	3,845	4,833	5,079	5,024	5,153	5,373
Right-of-use asset	2,605	2,248	1,872	1,473	1,050	602
Goodwill	—	—	—	—	—	6,525
Total assets	40,320	47,326	51,823	52,477	61,192	74,509
Accounts payable	2,288	3,761	2,261	4,513	4,614	4,262
Accrued liabilities	2,198	2,751	3,135	3,359	3,479	4,366
Total current liabilities	5,872	11,354	9,676	12,892	14,629	12,983
Lease liability, non-current	2,432	2,054	1,638	1,182	685	627
Total liabilities	20,236	23,658	20,233	21,610	24,560	26,876
Retained earnings	12,346	15,986	24,823	26,950	35,928	47,633
Total stockholders' equity	20,084	23,668	31,590	30,867	36,632	47,633
Total liabilities and equity	40,320	47,326	51,823	52,477	61,192	74,509
Common shares outstanding (cover page) thousands of shares	3,646	3,619	3,547	3,358	3,262	3,203

Fiscal years (PDEX's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	4,450	3,855	7,074	2,127	8,978	13,662
Stock-based compensation	901	1,275	766	605	555	688
Depreciation and amortization	686	726	857	1,160	1,239	1,394
Net cash from operating activities	(2,078)	(847)	5,462	6,199	(1,682)	7,242
Purchases of property and equipment	1,769	1,638	—	—	1,246	483
Net cash from investing activities	(3,710)	(1,235)	(885)	(2,233)	(238)	3,913
Share repurchases	5,537	1,606	1,547	3,505	3,504	3,408
Proceeds from long-term debt	9,139	2,000	5,284	—	—	—
Net cash from financing activities	3,088	(790)	(2,490)	(4,271)	(292)	(3,382)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Carlsmed	46,244	not reported	(7,358)*	27.3M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Myomo	11,219	11,705	(1,944)*	39.6M	6.9 quarters	Q2 FY26 10-QJun 30, 2026
Edap TMS	21,542	13,203	(3,691)*	37.5M	6.5 quarters	Q2 FY26 10-QJun 30, 2026
InspireMD	15,149	1,771	(10,895)*	46.5M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Cytosorbents	4,413	9,633	(583)*	62.8M	7.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.